Clinical

Dataset Information

A Screening Study Targeting Tumor-specific Antigens


ABSTRACT: The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by Gritstone bio. This may include the manufacturing of an individualized vaccine, which involves neoantigen prediction and generating a vaccine targeting neoantigens.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Stage Ii/iii Colon Cancer,Colonic Neoplasms

PROVIDER: 2398435 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR